Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 6/20 | 0.49 |
| ▸ | MAP4K1 | Q92918 | 11/20 | 0.47 |
| ▸ | ROS1 | P08922 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25947729 | 0.90 | MAP4K1 (0.57) | ALKMAP4K1ROS1EGFRBTK | |
| Phosphine SCHEMBL25950282 | 0.89 | ALK (0.48) | ALKMAP4K1ROS1EGFRAXL | |
| SCHEMBL25947471 | 0.87 | ALK (0.65) | ALKMAP4K1 | |
| SCHEMBL25947518 | 0.85 | ALK (0.52) | ALKMAP4K1AXLJAK3BTK | |
| SCHEMBL25947641 | 0.85 | ALK (0.52) | ALKMAP4K1AXLJAK3BTK | |
| SCHEMBL25947487 | 0.82 | ALK (0.56) | ALKMAP4K1AXL | |
| SCHEMBL25947502 | 0.81 | ALK (0.65) | ALKMAP4K1 | |
| SCHEMBL30446890 | 0.81 | MAP4K1 (0.58) | ALKMAP4K1ROS1EGFRBTK | |
| SCHEMBL25947493 | 0.78 | ALK (0.58) | ALKMAP4K1 | |
| SCHEMBL24716911 | 0.78 | ALK (0.62) | ALKMAP4K1ROS1EGFRAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | ALK 2067/4885MAP4K1 1/4885ROS1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.